RxDoctor Payments DataLook up a doctor →

Daniel Rothschild, MD

Interventional Cardiology · Louisville, KYNPI 1548525678

Payments from drug & device makers

$203,230in general payments, 2019–2025

Across 630 payments — averaging $322.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$78K
  • Inari Medical, Inc.$73K
  • Medtronic$36K
  • Boston Scientific$7K
  • Abbott$6K
  • Abiomed$999
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$71,24646%
  • Speaking & faculty fees$22,41315%
  • Grants$9,0006%
  • Travel & lodging$28,36618%
  • Food & beverage$23,02915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$203,230 in reported general payments places this provider in the 90th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$270,730
Medicare patients
1,411
Services billed
3,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$64,486
XareltoRivaroxaban18$21,845
BrilintaTicagrelor22$17,420
Repatha SureclickEvolocumab16$8,672
Prasugrel Hcl43$2,822
Ranolazine ErRanolazine13$2,514
ClopidogrelClopidogrel Bisulfate210$2,079
Metoprolol Succinate69$989
Rosuvastatin Calcium50$951
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide11$698
Warfarin Sodium56$559
Atorvastatin Calcium73$384
Carvedilol58$310
Isosorbide Mononitrate ErIsosorbide Mononitrate41$300
Losartan Potassium33$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$366$17,42022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →